9 Key Terms: China Medical Device & IVD Clinical Trials

Navigating China’s medical device and in vitro diagnostic (IVD) clinical trial requirements means getting to grips with a distinct set of regulatory terms. From clinical evaluation exemptions to overseas clinical data acceptance, these terms describe different aspects of how the National Medical Products Administration (NMPA) assesses clinical evidence.

These distinctions are more than semantics. Each term describes a specific aspect of how the National Medical Products Administration (NMPA) assesses clinical evidence, with practical implications for what data you need to generate and how you can use it in a registration application.

To help you make sense of the terminology, here are nine key concepts to help you navigate China’s medical device and IVD clinical trial requirements. Alternatively, explore Cisema's services for medical device Clinical Trials in China and contact us today to discuss your registration requirements.

1. Risk Classification

In China, every regulatory domino falls according to risk classification. The NMPA stratifies medical devices into Class I (low risk), Class II (moderate risk), and Class III (high risk), with IVDs following a parallel tiered framework. For a detailed breakdown, see our guides to medical device risk classification in China and IVD risk classification in China.

Rather than being a simple label, your product’s risk classification dictates your entire journey: it determines the allowable registration pathways, trial necessity, submission complexity, and oversight intensity.

Why it matters: Pinpointing your Chinese classification early is non-negotiable. A misstep here can invalidate your entire clinical strategy, as every downstream requirement hinges on this initial assignment.

2. Clinical Trial Exemptions

A clinical evaluation exemption allows qualifying medical devices or IVDs to avoid a clinical trial as part of the registration process when they meet the applicable NMPA criteria.

The NMPA regularly publishes and updates clinical evaluation exemption catalogues. Manufacturers should check the applicable:

• Catalogue of Medical Devices Exempt from Clinical Evaluation
• Catalogue of In Vitro Diagnostic Reagents Exempt from Clinical Trials

The distinction in catalogue titles is important. For medical devices, the exemption applies to the overall clinical evaluation process, meaning qualifying devices are exempt from both clinical trials and predicate comparisons. For IVDs, the exemption applies specifically to clinical trials; inclusion in the catalogue waives a formal trial, but a local clinical evaluation or validation study is typically still required.

Why it matters: Verifying exemption eligibility upfront reveals whether you can avoid a new clinical trial and clarifies exact dossier requirements from day one.

To better understand how these requirements apply to your product, see our guide on whether your medical device needs a clinical trial in China.

3. Predicate Device

A predicate device is a legally marketed reference device used to benchmark the safety and effectiveness of a new medical device. If a manufacturer can demonstrate substantial equivalence to a predicate device through a Clinical Evaluation Report (CER), new clinical trials may not be required.

The comparison may include:

• Intended use
• Technical characteristics
• Performance
• Biological characteristics

Simply finding a similar device on the Chinese market does not automatically make it a valid predicate. Unaddressed disparities in technological features, material biology, or clinical indications will break the chain of equivalence, forcing you back into generating primary clinical data.

Why it matters: Identifying a valid predicate can streamline your clinical evaluation and significantly reduce the scope of new clinical evidence required.

4. Overseas Clinical Data

The NMPA does not automatically accept clinical data simply because it satisfied another major global regulator (such as the US FDA or EU Notified Bodies). However, foreign data can be successfully leveraged to support Chinese medical device registration if it aligns with local regulatory expectations.

When evaluating foreign clinical data, the NMPA may assess factors including:

• Study design and methodology
• Study population
• Clinical endpoints
• Data quality
• Differences between the overseas study population and the intended Chinese population

Before committing to a submission strategy, manufacturers must systematically gap-analyze their foreign data against NMPA benchmarks to ensure acceptability.

Why it matters: Existing global clinical data may reduce the need for additional clinical studies in China, provided the data adequately address the applicable regulatory requirements.

5. Real-World Data (RWD)

Real-World Data (RWD) is clinical or healthcare data collected outside traditional clinical trials. Potential sources include patient-generated data, electronic health records, registries, and other real-world healthcare data.

While RWD rarely acts as a standalone substitute for a pivotal trial, it offers immense value as high-potency supplementary evidence. When traditional trials leave unresolved questions — or when studying rare indications — robust RWD can solidify your overall evidence portfolio.

To successfully leverage RWD, manufacturers must rigorously validate the data set's relevance, data quality, and chain of custody prior to submission.

Why it matters: RWD can provide additional evidence where conventional clinical data do not fully address a specific evidence requirement.

6. Clinical Trial Protocol

When a local medical device clinical trial in China is mandatory, the protocol acts as the technical and operational blueprint. It defines the study’s core structure: primary and secondary endpoints, patient eligibility, intervention methodologies, sample size calculations, and statistical analysis plans.

For trials executed in mainland China, the protocol must achieve a dual standard: adhering strictly to international Good Clinical Practice (GCP) while meeting NMPA-specific clinical requirements. Furthermore, it serves as the baseline document evaluated by site Ethics Committees.

Why it matters: A well-designed protocol helps ensure that the trial generates clinically relevant evidence that can support the intended registration strategy.

7. Ethics Committee Approval

Before enrolling participants at any trial site in China, the protocol and supporting clinical materials must be reviewed and approved by the corresponding Ethics Committee (EC). The committee assesses ethical considerations relating to the study, including participant rights, safety, informed consent, and the proposed research methodology.

Securing ethical clearance is a strict regulatory prerequisite. Finalizing your protocol is only the mid-point; zero clinical activity can occur until formal EC sign-off is granted across sites.

Why it matters: Formal ethics approval is legally required prior to participant enrollment, making it a critical milestone in your trial timeline.

8. Clinical Trial Record-Filing (Bei'an)

Transparency and formal oversight are core requirements of the NMPA framework. Before a China medical device clinical trial can launch, the study must undergo official project record-filing (bei’an) with the provincial-level Medical Products Administration (MPA) in the jurisdiction where the sponsor is located.

Rather than taking place through a simple public online platform, Article 40 of the Good Clinical Practice for Medical Devices (GCP) mandates a strict administrative sequence: the trial protocol must first secure Ethics Committee (EC) approval, and formal clinical contracts must be signed with the trial institution, before project record-filing can be submitted to the local regulatory authority.

During this setup phase, sponsors and manufacturers must also ensure that data collection, storage, and cross-border management strictly comply with applicable Chinese data privacy laws, including the Personal Information Protection Law (PIPL).

9. Clinical Trial Report (CTR)

A clinical trial isn't finished when the last patient completes their final visit — it is finished when the data is fully audited, analyzed, and synthesized. The Clinical Trial Report (CTR) is the definitive formal record summarizing the study.

A complete CTR systematically documents:

• Study methodology
• Patient Population
• Endpoints
• Results
• Safety Findings
• Conclusions

When a local study forms part of your registration pathway, the CTR serves as a core component of the final NMPA submission package.

Why it matters: The clinical trial does not end when patient follow-up is complete. The resulting data must be analyzed and documented in a form that can support the final regulatory submission.

Final Thoughts: Navigating Clinical Trials in China

Bringing a medical device or IVD to China doesn’t automatically mean jumping straight into a costly, time-consuming local trial. The best approach is about smart leverage, mapping out your full evidence landscape before signing off on local study protocols.

Whether that means qualifying for an exemption, proving predicate equivalence, or leveraging existing overseas clinical data, finding the right path early will save you months of work and budget. And if a local medical device clinical trial really is required? Treating it as an integrated piece of your overarching NMPA submission strategy ensures every piece of data moves you directly toward final approval.

That’s where having the right partner on the ground makes all the difference. At Cisema, we help you navigate each stage of this journey without the guesswork:

• Stress-test your strategy up front with clinical feasibility, exemption assessments, and GCP compliance checks
• Handle early prep work, including local type testing, protocol development, and Ethics Committee approvals
• Run compliant trials on the ground, taking care of site selection, contracting, monitoring, and safety reporting

Once the trial is complete, we handle the clinical data management, author your Clinical Trial Report (CTR), and guide your complete submission through the NMPA.

Whether you're looking to validate an exemption pathway or need end-to-end support running a medical device clinical trial in China, contact Cisema today to get your strategy moving in the right direction.

Further Information

Explore Cisema’s service for medical device clinical trials in China.

Learn more about Cisema's services for NMPA medical device registration in China.

Read more about Clinical Trials for medical devices in China:

• When Is a Clinical Trial Required for China NMPA Medical Device Registration?
• How China Medical Device Clinical Trial Strategy Affects NMPA Approval Timelines
• China NMPA Fee Catalogue for Drugs & Medical Devices

References

• Announcement of the National Medical Products Administration and National Health Commission on the Release of the 'Good Practice for Clinical Trials of Medical Devices' (2022 No. 28)《国家药监局 国家卫生健康委关于发布《医疗器械临床试验质量管理规范》的公告（2022年第28号）》
• Announcement of the National Medical Products Administration on Issuing the List of In Vitro Diagnostic Reagents Exempt from Clinical Trials (2025) (No. 23 of 2025) 《国家药监局关于发布免于进行临床试验体外诊断试剂目录（2025年）的通告（2025年第23号）》
• Announcement of the National Medical Products Administration on Issuing the Catalogue of Medical Devices Exempt from Clinical Evaluation (No. 19 of 2025) 国家药监局关于发布免于进行临床评价医疗器械目录的通告（2025年第19号）
• Announcement of the National Medical Products Administration on the Issuance of Five Technical Guidelines for Clinical Evaluation of Medical Devices and Five Other Guidelines (2021 No. 73) 《国家药监局关于发布医疗器械临床评价技术指导原则等5项技术指导原则的通告（2021年第73号）》
• Classification Rules for Medical Devices (Order No. 15 of the National Medical Products Administration)《医疗器械分类规则》（国家食品药品监督管理总局令第15号）
• Guideline for Registration Review on Clinical Trial Data Submission Requirements for Medical Devices《医疗器械临床试验数据递交要求注册审查指导原则（2021年第91号)》
• Measures for the Administration of Medical Device Registration and Filing《医疗器械注册与备案管理办法》
• Regulations on the Supervision and Administration of Medical Devices《医疗器械监督管理条例》
• Technical Guideline for Accepting Overseas Clinical Trial Data of Medical Devices《接受医疗器械境外临床试验数据技术指导原则（2018年第13号）》
• Technical Guideline for Comparative Description of Products Listed in the Catalogue of Medical Devices Exempt from Clinical Evaluation《列入免于临床评价医疗器械目录产品对比说明技术指导原则（2021年第73号）》
• Technical Guideline for Decision on Whether to Conduct Clinical Trials of Medical Devices《决策是否开展医疗器械临床试验技术指导原则》（2021年第73号）
• Technical Guideline for the Use of Real-World Data in Clinical Evaluation of Medical Devices《真实世界数据用于医疗器械临床评价技术指导原则（试行）（2020年第77号）》

‍